UPLIZNA Concentrate for solution for infusion Ref.[109666] Active ingredients: Inebilizumab

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Horizon Therapeutics Ireland DAC, 70 St. Stephens Green, Dublin 2, D02 E2X4, Ireland

Product name and form

Uplizna 100 mg concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to slightly yellow solution. The solution has a pH of approximately 6.0 and an osmolality of approximately 280 mOsm/kg.

Qualitative and quantitative composition

Each vial contains 100 mg of inebilizumab in 10 mL at a concentration of 10 mg/mL. The final concentration after dilution is 1.0 mg/mL.

Inebilizumab is a humanised monoclonal antibody produced in Chinese hamster ovary cell line by recombinant DNA technology.

Excipient with known effect: This medicinal product contains 16.1 mg of sodium per vial.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Inebilizumab

Inebilizumab is a monoclonal antibody that specifically binds to CD19, a cell surface antigen present on pre-B and mature B-cell lymphocytes, including plasmablasts and some plasma cells. Following cell surface binding to B lymphocytes, inebilizumab supports antibody-dependent cellular cytolysis (ADCC) and antibody-dependent cellular phagocytosis (ADCP). B cells are believed to play a central role in the pathogenesis of NMOSD. The precise mechanism by which inebilizumab exerts its therapeutic effects in NMOSD is unknown.

List of Excipients

Histidine
Histidine hydrochloride monohydrate
Sodium chloride
Trehalose dihydrate
Polysorbate 80 [E433]
Water for injections

Pack sizes and marketing

10 mL of concentrate in a Type 1 glass vial with an elastomeric stopper and a mist gray flip-off aluminium seal.

Pack size of 3 vials.

Marketing authorization holder

Horizon Therapeutics Ireland DAC, 70 St. Stephen’s Green, Dublin 2, D02 E2X4, Ireland

Marketing authorization dates and numbers

EU/1/21/1602/001

Date of first authorisation: 25 April 2022

Drugs

Drug Countries
UPLIZNA Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Japan, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.